Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Lymphoid 3Dermatologic 3Thoracic 2Breast 2Sarcoma 1Other neoplasm 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1

Conditions

Liposarcoma 1

Interventions

Cyclophosphamide 93Doxorubicin 92Radiotherapy 87Temozolomide 69Filgrastim 58Ifosfamide 55Bevacizumab 55Etoposide 48Gemcitabine 44Imatinib Mesylate 43Vincristine 40pembrolizumab 35pazopanib 34Peripheral Blood Stem Cell Transplantation 31Methotrexate 31Nivolumab 30Carboplatin 30fludarabine phosphate 29Irinotecan 29Cisplatin 28Paclitaxel 26Melphalan 26Magnetic Resonance Spectroscopy 26Docetaxel 25Busulfan 25Trabectedin 24apatinib 22Specimen Handling 21Sirolimus 21Antilymphocyte Serum 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × tanespimycin × Sarcoma × Clear all
NCT00969917 2015-04-14

Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Infinity Pharmaceuticals, Inc.

Phase 2 Withdrawn
Sarcoma

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡